New York, Jan 3, 2026, 14:41 ET — Market closed
- Thermo Fisher closed Friday up 2.25% at $592.51, beating the broader market.
- The stock finished about 3% below its 52-week high on above-average volume.
- Focus shifts to Jan. 29 earnings and a busy U.S. data calendar next week.
Thermo Fisher Scientific Inc NYSE:TMO shares rose 2.25% to $592.51 on Friday, outpacing a modest gain in the S&P 500. The life-sciences tools maker ended the session about 3% below its 52-week high, with trading volume above its 50-day average, according to MarketWatch data.
The move matters because it keeps Thermo Fisher near record territory as investors start to position for late-January earnings. With the stock already priced at a premium to many healthcare names, the next set of guidance and order commentary is likely to drive the next leg.
Strategists have warned that rich equity valuations leave less room for disappointment as earnings season approaches. “There is no way to sugar coat it—the S&P 500 is expensive,” Bank of America U.S. equity strategist Savita Subramanian said in a Jan. 2 note. Investing
A 52-week high is the stock’s highest level over the past year, a marker many traders treat as a near-term resistance point. Thermo Fisher’s sits at $610.97, close enough to Friday’s finish to keep technical watchers engaged.
Peers in the life-sciences tools group also advanced in the same session, with Agilent Technologies up 1.38% and Danaher up 0.65%, MarketWatch data showed.
Thermo Fisher, based in Waltham, Massachusetts, sells lab instruments, diagnostics and outsourced services used in drug development and medical research. Investors often treat its results as a read-through on spending by large pharmaceutical companies, biotech firms and academic labs.
Thermo Fisher said it will release fourth-quarter and full-year 2025 results before the market opens on Thursday, Jan. 29, and hold a conference call at 8:30 a.m. ET.
Investors will be watching for management’s outlook for 2026, including any change in demand for high-end instruments and services. Updates on order trends and customer budgets tend to carry extra weight for life-sciences tools companies early in the year.
On Wall Street, the average recommendation is “overweight” — meaning analysts expect the stock to outperform its sector or benchmark — and the average price target is about $644, according to MarketWatch’s analyst estimates page. MarketWatch
Thermo Fisher is also working toward closing its planned purchase of clinical-trial services provider Clario Holdings, a deal it said in October is expected to be completed by the middle of 2026, subject to regulatory approvals.
Before the next session, traders will wade into a dense calendar of U.S. indicators that can move rate expectations. The Bureau of Labor Statistics has the December employment report scheduled for Jan. 9 and the December consumer price index due Jan. 13, while ISM manufacturing and services surveys are also on tap next week.
For Thermo Fisher, shifts in yields and the dollar can change the market’s appetite for large-cap healthcare stocks that trade at high earnings multiples. Stronger data that keeps rates elevated can compress valuations; softer data can support them.
With the stock back near its 52-week high, $610.97 is the level many short-term traders will watch for a breakout or another stall. The bigger test comes on Jan. 29, when Thermo Fisher’s results and outlook will set expectations for how investors price the stock into 2026.
Related articles: Earnings Reports
